dengu
viru
denv
positivesens
rna
viru
transmit
mosquito
vector
primarili
aed
spp
consist
four
often
cocircul
serotyp
genu
flaviviru
serotyp
compris
multipl
distinct
genotyp
includ
sylvat
genotyp
infect
wild
nonhuman
primat
nhp
human
dengu
acut
febril
diseas
ie
classic
dengu
fever
df
accompani
rash
headach
eye
pain
arthralgia
laboratori
find
transient
neutropenia
ast
alt
elev
less
frequent
thrombocytopenia
febril
period
circul
viru
viremia
viral
rna
rnaemia
often
detect
cellbas
genet
amplif
assay
respect
approxim
million
case
df
report
unreport
case
estim
increas
annual
global
incid
million
includ
death
due
sever
form
diseas
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
major
risk
factor
dhfdss
presenc
serotyp
crossreact
antibodi
initi
primari
denv
infect
individu
lead
enhanc
viral
replic
second
infect
heterolog
serotyp
potenti
immunemedi
enhanc
viral
replic
complic
vaccin
develop
effort
asid
immun
defici
murin
model
macaqu
wide
accept
anim
model
preclin
evalu
dengu
vaccin
candid
denv
challeng
typic
administ
subcutan
sc
inject
model
endpoint
usual
inappar
infect
manifest
viremia
rather
overt
diseas
exampl
tetraval
dengu
vaccin
undergon
comprehens
anim
clinic
trial
dengvaxia
exhibit
overal
efficaci
vaccin
rhesu
macaqu
challeng
denv
serotyp
sc
rout
measur
protect
viremia
howev
vaccin
found
approxim
efficaci
overal
human
concern
dengueseroneg
children
receiv
vaccin
greater
risk
hospit
sever
virolog
confirm
dengu
subsequ
denv
natur
infect
compar
unvaccin
children
unclear
macaqu
model
instanc
fail
demonstr
limit
vaccin
critic
differ
observ
preclin
field
efficaci
safeti
data
dengvaxia
underscor
need
predict
anim
model
test
futur
dengu
vaccin
candid
previous
hypothes
limit
util
rhesu
macaqu
accur
predict
vaccin
efficaci
may
relat
number
factor
use
highpassag
noncontemporari
denv
strain
rel
low
viremia
level
observ
macaqu
assess
vaccin
efficaci
base
mainli
degre
reduct
postchalleng
denv
replic
marker
eg
viremia
rnaemia
neglect
biolog
paramet
associ
human
dengu
infect
may
consid
proxi
clinic
diseas
address
limit
demonstr
low
cellpassag
level
contemporari
denv
clinic
isol
brazil
induc
viremia
higher
magnitud
longer
durat
compar
previous
report
viremia
kinet
macaqu
also
chang
cytokin
profil
similar
patient
acut
df
furthermor
show
assess
vaccin
efficaci
combin
viremia
rnaemia
measur
character
chang
relev
biolog
marker
safeti
signal
associ
dengu
vaccin
could
detect
scinocul
macaqu
model
howev
despit
improv
model
demonstr
clinic
sign
viremiarnaemia
onset
occur
day
postchalleng
remain
low
term
magnitud
durat
compar
viremiarnaemia
report
sever
dengu
patient
previou
attempt
develop
dengu
diseas
model
nhp
employ
intraven
iv
administr
high
challeng
viru
dose
atyp
rout
challeng
eg
intramuscular
inject
far
remov
condit
natur
vectormedi
infect
util
nonmacaqu
speci
case
demonstr
diseas
sign
transient
rash
coagulopathi
elev
liver
enzym
howev
result
studi
often
difficult
reproduc
possibl
due
unrecogn
variabl
includ
compar
sc
inocul
control
macaqu
comparison
sc
challeng
altern
rout
administr
evalu
macaqu
challeng
intraderm
id
rout
seroconvert
rapidli
challeng
sc
rout
macaqu
challeng
iv
rout
exhibit
higher
peak
rnaemia
titer
compar
challeng
id
sc
small
group
macaqu
infect
sc
id
iv
rout
exhibit
differ
tissu
distribut
viru
group
exhibit
transient
day
low
level
viremia
effect
prior
denv
exposur
immun
subsequ
denv
infect
also
explor
macaqu
studi
util
sequenti
infect
passiv
transfer
subneutr
concentr
pool
human
denvimmun
sera
denvspecif
monoclon
antibodi
demonstr
significantli
higher
denv
viremia
titer
compar
nonimmun
control
addit
anim
denv
serotyp
sequenti
infect
studi
exhibit
reduc
viremia
indic
level
crossprotect
togeth
studi
indic
observ
human
heterolog
denv
infect
wane
insuffici
humor
immun
associ
nhp
increas
denv
replic
effect
natur
mosquito
vector
andor
mosquito
salivari
protein
msp
cours
denv
infect
rigor
studi
nhp
possibl
mosquito
vector
play
essenti
role
determin
outcom
infect
term
primari
target
cell
viru
dissemin
pathway
immun
activ
may
impact
diseas
sever
bloodfeed
mosquito
vertebr
host
initi
probe
result
physic
damag
epithelium
vasculatur
well
simultan
introduct
viru
msp
cutan
layer
skin
msp
contain
biolog
activ
protein
modul
host
hemostasi
immun
respons
turn
facilit
bloodfeed
viru
transmiss
effect
msp
mosquitoborn
viral
infect
review
previous
includ
alter
vascular
permeabl
denv
infect
chang
cytokin
innat
signal
profil
decreas
express
increas
express
denv
chikungunya
viru
chikv
west
nile
viru
wnv
infect
migrat
monocyt
neutrophil
eosinophil
plasma
cell
site
infect
denv
chikv
wnv
well
increas
wnv
neurovirul
addit
aed
aegypti
msp
increas
preval
diseas
sign
extend
virem
period
denvinfect
human
mice
variou
method
util
incorpor
msp
arboviru
research
includ
salivari
gland
extract
sge
feed
infecti
mosquito
use
feed
mosquito
offer
natur
relev
exposur
method
sge
allow
greater
control
reproduc
administ
dose
attempt
increas
clinic
relev
dengu
macaqu
model
compar
differ
viral
infect
modal
includ
live
mosquito
vectormedi
id
inocul
viru
without
msp
convent
sc
viral
inocul
use
lowpassag
ie
near
wildtyp
contemporan
denv
clinic
isol
order
reduc
impact
variat
past
exposur
msp
antigen
anim
studi
prime
multipl
sequenti
exposur
uninfect
feed
ae
aegypti
expos
denv
examin
viral
replic
magnitudekinet
host
immun
respons
follow
primari
infect
thereaft
follow
secondari
infect
either
homolog
heterolog
macaqu
infect
mosquito
imf
group
demonstr
peak
serum
infecti
viru
viremia
viral
rna
rnaemia
titer
significantli
higher
achiev
sc
id
idsg
infect
modal
respect
fig
durat
viremia
imf
group
also
significantli
longer
compar
id
idsg
group
sc
group
wherea
durat
rnaemia
imf
group
significantli
longer
idsg
group
sc
id
group
consid
magnitud
durat
viremia
estim
area
curv
auc
auc
also
significantli
greater
imf
group
compar
three
group
although
rnaemia
auc
similar
imf
sc
group
significantli
greater
idsg
group
rnaemia
auc
id
group
significantli
differ
group
mean
time
detect
onset
viremia
imf
group
day
significantli
longer
compar
three
group
day
togeth
result
demonstr
replic
kinet
delay
increas
imf
term
auc
peak
magnitud
compar
modal
viru
deliveri
time
denv
presenc
peak
peripher
blood
imf
group
macaqu
close
resembl
publish
dengu
human
infect
model
averag
viremia
onset
day
sc
group
macaqu
averag
viremia
onset
day
agreement
previou
estim
surprisingli
addit
sge
id
inject
rout
result
kinet
observ
imf
group
suggest
direct
mosquito
deliveri
differ
simpl
inclus
salivari
gland
compon
denv
inoculum
importantli
discount
potenti
differ
deliv
dose
imf
needleinocul
group
contribut
factor
result
estim
dose
denv
deliv
mosquito
extens
investig
may
also
depend
strain
mosquito
viru
use
method
quantiti
determin
one
estim
expector
ae
aegypti
capillari
tube
determin
maximum
approxim
pfu
genom
equival
anoth
estim
differ
strain
expector
ae
albopictu
suspend
droplet
measur
rang
approxim
mosquito
infecti
would
translat
minimum
infecti
virion
latter
estim
consist
needleinocul
dose
use
pfu
estim
west
nile
viru
transmiss
feed
anim
rang
pfu
depend
mosquito
speci
test
thrombocytopenia
leukopenia
decreas
lymphocyt
monocyt
neutrophil
count
elev
percent
monocyt
elev
level
aminotransferas
consid
biolog
hallmark
dengu
fever
df
human
determin
hematolog
serum
chemistri
paramet
impact
infect
modal
evalu
blood
serum
sampl
collect
primari
infect
day
fig
similar
df
patient
group
demonstr
signific
decreas
absolut
white
blood
cell
wbc
lymphocyt
neutrophil
count
wherea
differenti
show
increas
percent
monocyt
day
also
increas
ast
day
compar
baselin
level
group
alt
except
id
group
signific
decreas
rbc
count
hemoglobin
hematocrit
hct
rel
baselin
valu
observ
group
day
well
signific
increas
reticulocyt
count
group
day
latter
like
attribut
recoveri
daili
blood
collect
betweengroup
comparison
reveal
absolut
wbc
count
day
significantli
lower
idsg
group
versu
id
imf
group
neutrophil
count
also
significantli
lower
group
compar
imf
group
mean
ast
level
upper
limit
normal
observ
idsg
imf
group
idsg
group
mean
ast
level
significantli
higher
observ
sc
id
group
although
mean
platelet
count
fell
baselin
sc
idsg
group
remain
within
normal
refer
rang
nevertheless
mean
platelet
count
sc
group
still
significantli
lower
imf
group
addit
signific
chang
mean
valu
baselin
signific
differ
group
present
tabl
importantli
exclud
differ
might
detect
time
point
postchalleng
particularli
given
differ
denv
replic
kinet
describ
administr
site
skin
biopsi
collect
prior
primari
exposur
well
day
postexposur
examin
local
inflamm
ie
dermatitispannicul
immun
cellular
infiltr
biopsi
sampl
score
correspond
lack
local
inflammationcellular
infiltr
correspond
mark
inflammationcellular
infiltr
fig
none
anim
sc
group
score
baselin
exposur
anim
id
group
score
baselin
score
postexposur
contrast
idsg
group
anim
score
postexposur
anim
score
postexposur
similarli
imf
group
anim
score
postexposur
anim
score
postexposur
cumul
anim
idsg
imf
group
show
skin
inflammationcellular
infiltr
within
exposur
albeit
minim
mild
level
compar
anim
virusonli
group
altogeth
data
implic
mosquitobas
factor
impetu
inflamm
assess
whether
infect
modal
impact
earli
immun
respons
site
administr
transcript
analys
conduct
skin
biopsi
sampl
site
rna
transcript
median
express
level
shown
group
time
point
fig
group
express
elev
baselin
eotaxin
chemotact
eosinophil
chemotact
mononuclear
cell
express
pleotrop
immunomodulatori
cytokin
best
known
inhibit
type
inflamm
elev
group
except
sc
express
level
rigi
two
doublestrand
cytoplasm
rna
pattern
recognit
receptor
prr
elev
sc
group
express
level
elev
two
mosquitorel
group
idsg
imf
statist
differ
assess
group
rel
sc
group
id
group
express
significantli
lower
sc
group
express
significantli
higher
day
idsg
group
rel
sc
group
express
level
eotaxin
significantli
elev
rant
also
significantli
elev
imf
induc
significantli
increas
transcript
tradit
cytokin
follow
elev
decreas
decreas
rigi
compar
sc
group
taken
togeth
transcript
respons
observ
would
indic
imfinduc
shift
away
earli
antivir
respons
observ
sc
inocul
site
initi
replic
similar
previou
observ
murin
model
assess
whether
parallel
exist
immun
transcript
express
detect
administr
site
skin
system
cytokin
product
evid
peripher
blood
cytokin
chemokin
growth
factor
serum
assess
follow
primari
infect
fig
cytokin
product
profil
serum
observ
compar
transcript
express
observ
administr
site
biopsi
paramet
present
assay
howev
observ
cytokin
product
outsid
cutoff
rang
specif
certain
group
exampl
elev
sc
group
wherea
elev
id
idsg
group
elev
idsg
imf
group
none
cytokin
test
express
outsid
rang
exclus
imf
group
contrast
reduc
exclus
imf
group
preced
day
peak
rnaemia
synchron
decreas
notabl
cytokin
util
heterodimer
cytokin
receptor
critic
prolif
prosurviv
factor
activ
cell
interestingli
onset
elev
vegf
cytokin
involv
angiogenesi
vascular
permeabl
coincid
day
peak
rnaemia
group
level
group
elev
vegf
earli
day
ill
propos
predictor
sever
dengu
human
due
dispar
administr
site
respons
serum
cytokin
product
system
focu
remaind
assess
herein
administr
site
transcript
analys
conduct
latter
phase
studi
neutral
antibodi
titer
four
denv
serotyp
assess
sc
imf
group
month
postprimari
exposur
geometr
mean
titer
month
group
sc
imf
group
shown
fig
longitudin
titer
across
time
point
shown
individu
anim
sc
imf
group
fig
month
titer
highest
infect
serotyp
moder
low
undetect
irrespect
group
neutral
antibodi
titer
continu
develop
time
moder
rise
geometr
mean
titer
month
month
addit
titer
undetect
month
rose
geometr
mean
titer
month
similar
lack
wane
crossneutr
antidenv
antibodi
rhesu
macaqu
report
previous
abil
serial
dilut
month
sera
promot
antibodydepend
infect
enhanc
ade
vitro
strain
use
secondari
infect
also
assess
approxim
increas
mean
peak
infect
presenc
sera
rel
neg
control
sera
sc
imf
group
howev
statist
differ
observ
two
group
ade
curv
overlaid
anim
shown
fig
anim
detect
titer
ade
peak
observ
dilut
greater
indic
undilut
serum
anim
would
expect
neutral
viru
infect
mediat
ade
shown
tabl
month
primari
infect
sc
imf
group
split
two
subgroup
five
anim
homolog
reexpos
strain
sc
imf
heterolog
expos
sc
imf
two
addit
group
anim
includ
infect
modal
control
exposur
macaqu
sc
imf
primari
infect
group
serum
rnaemia
viremia
measur
statist
comparison
made
peak
titer
observ
auc
day
onset
durat
interestingli
shown
fig
imf
group
differ
significantli
rnaemia
peak
auc
onset
durat
compar
sc
yet
demonstr
significantli
higher
viremia
peak
titer
auc
discrep
imf
sc
observ
primari
infect
suggest
serotyp
strainspecif
relationship
infect
modal
possibl
differ
vertebr
vector
infect
differ
interact
specif
msp
serotyp
differ
onset
durat
viremia
nhp
identifi
previous
suggest
imf
model
like
also
use
investig
differ
addit
specif
interact
individu
msp
denv
describ
previous
util
model
allow
interact
may
prove
critic
studi
denv
pathogenesi
vaccin
develop
heterolog
exposur
differ
primari
infect
fig
opposit
studi
hypothesi
viremiarnaemia
would
unchang
increas
heterolog
infect
compar
primari
infect
mani
viremiarnaemia
paramet
reduc
detect
secondari
sc
sc
secondari
imf
imf
compar
correspond
primari
sc
imf
group
durat
rnaemia
sc
imf
group
significantli
shorten
day
respect
rnaemia
auc
significantli
less
group
compar
primari
infect
also
signific
decreas
peak
rnaemia
imf
group
rel
primari
imf
data
may
explain
unexpectedli
longlast
high
titer
cross
neutral
activ
result
primari
infect
primari
infect
rnaemia
peak
auc
durat
differ
significantli
imf
sc
contrast
rnaemia
onset
imf
significantli
delay
rel
sc
unlik
primari
imf
imf
demonstr
detect
viremia
measur
plaqu
titrat
importantli
anim
anim
basi
consist
observ
plaqu
product
serum
sampl
genom
equivalentsml
least
secondari
infect
none
anim
imf
genom
equivalentsml
peak
reach
threshold
surprisingli
replic
homolog
reexposur
group
observ
peripheri
primari
exposur
hematolog
clinic
chemistri
assess
studi
day
post
primari
homolog
heterolog
exposur
fig
similar
primari
exposur
hct
decreas
percent
monocyt
increas
significantli
sc
imf
group
day
rel
baselin
contrari
primari
exposur
wbc
count
sc
imf
chang
significantli
baselin
addit
day
lymphocyt
neutrophil
count
decreas
level
alt
increas
significantli
rel
baselin
imf
sc
wherea
chang
extend
sc
imf
group
primari
exposur
regard
homolog
secondari
exposur
day
wbc
neutrophil
count
decreas
ast
level
increas
significantli
rel
baselin
imf
sc
regard
heterolog
secondari
exposur
day
wbc
count
neutrophil
count
decreas
significantli
rel
baselin
sc
imf
lymphocyt
count
decreas
ast
level
increas
significantli
sc
percent
monocyt
increas
significantli
imf
seen
primari
exposur
signific
decreas
rbc
count
hemoglobin
hct
rel
baselin
detect
group
day
betweengroup
comparison
reveal
signific
differ
reflect
administr
rout
rather
exposur
histori
wbc
count
monocyt
count
significantli
lower
percent
lymphocyt
higher
imf
rel
sc
albumin
significantli
lower
imf
compar
sc
well
imf
rel
sc
reduct
albumin
concentr
suggest
predictor
dhf
human
lymphocyt
count
significantli
lower
sc
rel
imf
compar
heterolog
versu
homolog
secondari
exposur
percent
monocyt
basophil
significantli
higher
sc
rel
sc
lastli
percent
basophil
significantli
higher
sc
rel
sc
signific
mean
chang
baselin
signific
differ
group
present
tabl
administr
site
skin
biopsi
collect
prior
denv
exposur
day
postexposur
examin
local
inflamm
ie
dermatitispannicul
immun
cellular
infiltr
analysi
reveal
dermatitispannicul
score
baselin
skin
biopsi
specimen
fig
none
anim
sc
score
baselin
wherea
anim
imf
score
score
reexposur
three
anim
sc
score
anim
sc
score
similarli
anim
imf
score
score
anim
imf
score
serum
cytokin
assess
follow
primari
homolog
heterolog
exposur
perform
primari
infect
fig
elev
rel
baselin
four
group
receiv
exposur
homolog
reexposur
group
elev
product
cytokin
began
immedi
follow
day
peak
viremiarnaemia
elev
sc
also
begin
peak
rnaemiaviremia
elev
three
group
expos
imf
observ
primari
imf
group
exhibit
decreas
concentr
imf
group
though
earlier
time
point
vegf
exhibit
elev
product
multipl
time
point
three
sc
exposur
group
contrast
primari
infect
time
vegf
product
associ
day
peak
rnaemia
discern
pattern
neutral
antibodi
titer
administ
serotyp
assess
day
follow
secondari
denv
primari
exposur
geometr
mean
titer
gmt
sc
imf
group
respect
follow
primari
exposur
tabl
gmt
anim
sc
imf
group
increas
respect
follow
secondari
heterolog
exposur
howev
detect
boost
titer
follow
secondari
homolog
exposur
either
modal
gmt
even
wane
sc
imf
group
respect
compar
month
preinfect
titer
lack
boost
suggest
neglig
level
replic
follow
homolog
reexposur
could
indic
steril
immun
result
primari
infect
irrespect
infect
modal
howev
signific
chang
observ
hematolog
paramet
serum
cytokin
product
follow
homolog
exposur
stand
contrast
hypothesi
suggest
need
character
fluctuat
paramet
repeat
denv
exposur
anesthet
blood
sampl
collect
model
present
studi
demonstr
effect
vari
infect
modal
denv
nonhuman
primat
model
includ
chang
time
magnitud
denv
replic
kinet
peripheri
concentr
numer
hematolog
biochem
immunolog
paramet
compar
typic
subcutan
inocul
mani
effect
serotyp
straindepend
addit
salivari
gland
extract
intraderm
inocul
suffici
recapitul
denv
infect
via
imf
present
studi
denv
infect
rhesu
macaqu
via
imf
appear
import
step
forward
better
recapitul
natur
human
infect
although
addit
factor
could
contribut
observ
outcom
potenti
confound
variabl
studi
denv
pathogenesi
follow
natur
infect
degre
subject
previous
expos
mosquito
saliva
salivari
antigen
bloodfeed
mosquito
preval
antibodi
msp
given
speci
human
sera
vari
age
season
report
high
ae
aegypti
endem
area
signific
associ
also
found
presenc
antibodi
individu
ae
aegypti
salivari
protein
sera
patient
secondari
dengu
infect
clinic
present
addit
preexposur
mice
feed
ae
aegypti
result
increas
wnv
neurovirul
mortal
upon
subsequ
viral
infect
via
vector
mosquito
macaqu
present
studi
obtain
coloni
hous
outdoor
expos
bite
variou
speci
mosquito
natur
environ
given
improb
locat
cohort
anim
control
group
includ
thu
impact
sensit
msp
infect
pars
physiolog
impact
msp
infect
system
discuss
quantiti
viru
inocul
probe
feed
mosquito
rel
amount
needleinocul
studi
remain
uncharacter
exclud
increas
peak
titer
seen
mosquitoexpos
anim
might
due
higher
overal
inocula
per
anim
unlik
light
publish
literatur
systemat
review
nhp
model
denv
conclud
increas
dose
significantli
associ
shorter
time
detect
viremia
shorter
durat
detect
viremia
wherea
time
present
studi
similar
increas
mosquitoexpos
anim
rel
needleinocul
anim
addit
anoth
review
nhp
model
denv
conclud
higher
dose
appear
result
higher
viremia
includ
dose
high
pfu
inject
intraven
differ
earli
viral
recognit
effector
molecul
product
associ
challeng
modal
chosen
assess
vaccin
efficaci
could
great
influenc
downstream
replic
pathogenesi
denv
therebi
influenc
appar
efficaci
candid
vaccin
data
present
herein
point
need
inclus
vectorbas
administr
investig
arboviru
system
human
public
health
relev
research
conduct
anim
use
protocol
approv
wrairnmrc
institut
anim
care
use
committe
institut
approv
letter
studi
provid
journal
research
conduct
aaalaci
accredit
facil
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nrc
public
edit
materi
review
walter
reed
armi
institut
research
object
present
andor
public
opinion
assert
contain
herein
privat
view
author
constru
offici
reflect
true
view
depart
armi
depart
defens
anim
hous
individu
virem
period
studi
pairhous
remaind
studi
light
cycl
room
air
chang
per
hour
anim
fed
old
world
primat
chow
qualiti
lab
product
elkridg
md
twice
daili
fresh
fruit
least
three
time
week
water
ad
libitum
environment
enrich
provid
form
cage
complex
food
treat
opportun
forag
rotat
sever
toy
puzzl
period
access
activ
cage
permit
climb
jump
swing
altern
day
televis
music
anim
anesthet
combin
ketamin
mgkg
acepromazin
mgkg
intramuscularli
prior
procedur
studi
perform
protocol
nontermin
acquisit
healthi
adult
femal
chines
origin
coloni
bred
rhesu
macaqu
facilit
covanc
research
product
nih
primat
center
prior
place
protocol
anim
test
found
neg
antibodi
japanes
enceph
viru
wnv
yellow
fever
viru
lowdilut
screen
use
viru
neutral
assay
prior
initi
infect
anim
assign
particular
order
attempt
balanc
age
weight
four
experiment
infect
group
group
differ
viru
exposur
modal
shown
tabl
prior
infect
anim
preexpos
feed
aed
aegypti
rockefel
strain
mosquito
prime
immunolog
mosquito
salivari
antigen
carton
mosquito
allow
feed
anim
week
prior
infect
four
week
last
mosquito
prime
anim
infect
accord
group
viru
administ
shave
skin
separ
locat
space
least
cm
apart
dorsal
aspect
method
specifi
tabl
skin
punch
biopsi
collect
immedi
infect
day
postinfect
character
inflamm
transcript
differ
infect
site
blood
sampl
collect
prior
infect
baselin
infect
hour
daili
day
day
assess
circul
infecti
viru
viremia
viral
rna
rnaemia
serum
antibodi
cytokin
cbcdifferenti
serum
chemistri
follow
primari
infect
followup
blood
sampl
collect
approxim
monthli
interv
allow
longitudin
assess
serum
neutral
antibodi
titer
administ
secondari
infect
weight
bodi
temperatur
puls
respir
rate
record
anim
everi
time
point
assess
primari
infect
sc
imf
group
select
secondari
infect
administ
approxim
month
primari
infect
anim
origin
sc
imf
group
divid
subgroup
anim
two
new
control
group
anim
sc
imf
ad
protocol
serv
primari
infect
control
shown
tabl
preexpos
feed
ae
aegypti
anim
expos
group
either
homolog
reexposur
heterolog
exposur
primari
exposur
case
control
follow
primari
infect
studi
phase
anim
monitor
develop
clinic
sign
diseas
blood
sampl
infect
site
skin
biopsi
collect
assess
virolog
hematolog
immunolog
paramet
anim
expos
viru
one
four
method
subcutan
inject
sc
ii
intraderm
inject
id
iii
intraderm
inject
also
contain
mosquito
salivari
gland
extract
idsg
iv
feed
infecti
mosquito
imf
inject
denv
stock
eagl
minim
essenti
medium
heatinactiv
fetal
bovin
serum
fb
dilut
need
unsuppl
emem
obtain
viral
load
final
inoculum
pfu
per
anim
administr
three
separ
site
dorsal
aspect
torso
except
mosquito
feed
unless
otherwis
note
viral
dose
administ
inject
site
four
anim
partial
dose
deliv
idsg
group
due
clog
microneedl
deliveri
apparatu
dose
deliv
rang
intend
volum
equat
pfu
consid
neglig
sc
inject
util
ml
dose
ml
syring
gaug
needl
id
inject
util
dose
administ
use
debioject
devic
debiotech
sa
switzerland
equip
microneedl
idsg
inject
addit
includ
equival
five
salivari
gland
pb
equat
minimum
feed
five
mosquito
sge
prepar
previous
describ
filter
prior
use
imf
group
mosquito
canist
restrict
open
allow
feed
per
three
site
total
mosquito
per
anim
mosquito
allow
feed
probe
least
fed
replet
per
locat
ten
minut
tabl
denv
use
nhp
infect
recent
circul
strain
brazil
isol
mosquito
cell
febril
patient
rio
de
janeiro
strain
campo
strain
respect
virus
kindli
provid
dr
ana
bispo
de
filippi
describ
previous
prepar
stock
nhp
infect
vero
cell
cultur
supernat
contain
fb
harvest
centrifug
pellet
larg
debri
clarifi
supernat
plaqu
titrat
singleus
aliquot
frozen
prior
use
vero
stock
follow
origin
isol
cell
use
infect
nhp
mosquito
stock
sequenc
use
specif
primer
respect
illumina
miseq
platform
describ
authent
content
genom
assembl
use
inhous
develop
refer
map
pipelin
ngsmapper
http
githubcomvdbwrairngsmapp
addit
strain
western
pacif
respect
yfv
strain
jev
strain
util
elisa
andor
prnt
assay
virus
prnt
assay
produc
vero
cell
virus
elisa
assay
produc
cell
viru
elisa
purifi
ultracentrifug
sucros
solut
viru
pellet
resuspend
pb
laboratori
strain
ae
aegypti
rockefel
maintain
constant
environment
condit
rel
humid
light
dark
photoperiod
provid
sucros
solut
ad
libitum
mosquito
coldanesthet
expos
denv
intrathorac
inocul
use
microcapillari
needl
fix
microinject
apparatu
mosquito
inject
pfuml
pfuml
stock
mosquito
util
feed
nhp
day
post
inocul
method
valid
prior
studi
start
demonstr
infect
mosquito
salivari
gland
either
stock
viru
measur
use
plaqu
titrat
follow
mosquito
feed
needl
inocul
site
administr
biopsi
time
cours
sequenc
use
biopsi
punch
skin
biopsi
dissect
crosssect
portion
one
portion
immedi
submerg
neutral
buffer
formalin
histopatholog
analysi
case
primari
infect
anoth
portion
immedi
submerg
rnalat
solut
thermo
fisher
scientif
accord
manufactur
suggest
volum
preserv
time
subsequ
rna
extract
third
viru
administr
site
biopsi
system
infect
clear
day
standard
plaquereduct
neutral
test
prnt
vero
cell
monolay
use
screen
prestudi
sera
determin
serolog
anim
dilut
heatinactiv
sera
neutral
antibodi
titer
heatinactiv
sera
primari
infect
secondari
infect
phase
experi
determin
use
highthroughput
flow
cytometrybas
neutral
assay
previous
describ
serial
dilut
sera
mix
equal
volum
viru
dilut
achiev
infect
cellswel
incub
incub
equal
volum
medium
supplement
fb
penicillinstreptomycin
lglutamin
nonessenti
amino
acid
contain
cell
ad
serumviru
mixtur
incub
h
overnight
humidifi
incub
follow
overnight
incub
cell
fix
permeabil
immunostain
flaviviru
groupreact
mous
monoclon
antibodi
secondari
polyclon
goat
antimous
igg
peconjug
antibodi
bd
bioscienc
percent
infect
cell
quantifi
bd
accuri
plu
flow
cytomet
bd
bioscienc
data
analyz
nonlinear
regress
determin
endpoint
titer
graphpad
prism
vitro
antibodydepend
enhanc
denv
infect
quantifi
previous
describ
begin
twofold
serial
dilut
heatinactiv
day
sera
incub
viru
suffici
amount
infect
cell
mixtur
ad
plate
contain
cell
per
well
duplic
cell
infect
h
overnight
humidifi
incub
process
quantif
continu
outlin
method
foldinfect
rel
control
serum
report
plaqu
titrat
denv
inocula
sera
determin
standard
plaqu
assay
duplic
vero
cell
monolay
limit
detect
plaqueform
unitsml
pfuml
primari
infect
sampl
pfuml
secondari
infect
sampl
valu
undetect
sampl
replac
pfuml
respect
purpos
statist
analysi
graph
valu
onehalf
theoret
minimum
one
detect
plaqu
multipli
assay
dilut
factor
respect
achiev
per
ml
concentr
denv
sera
determin
previous
describ
modif
probe
fluorophor
chang
joe
rna
extract
sera
day
use
qiaamp
viral
rna
mini
qiacub
instrument
elut
rna
quantifi
qrtpcr
use
superscript
iii
platinum
onestep
qrtpcr
kit
thermo
fisher
scientif
quantstudio
realtim
pcr
instrument
thermo
fisher
scientif
denv
rnaemia
calcul
genom
equival
ge
per
ml
use
intern
standard
curv
serial
dilut
vitrotranscrib
rna
limit
quantit
defin
detect
standard
curv
dilut
least
replic
curv
test
assay
gereact
valu
undetect
sampl
replac
geml
purpos
statist
analysi
graph
valu
onehalf
theoret
minimum
one
detect
copi
per
reaction
multipli
assay
dilut
factor
achiev
per
ml
concentr
milliplex
map
nonhuman
primat
cytokinechemokin
panel
ii
kit
emd
millipor
use
determin
concentr
differ
cytokin
chemokin
growth
factor
present
serum
eotaxin
gcsf
gmcsf
vegf
kit
use
accord
manufactur
instruct
data
acquir
magpix
instrument
biorad
process
use
xponent
softwar
luminex
corp
protein
standard
provid
kit
standard
curv
gener
standard
dilut
panel
panel
assay
buffer
concentr
rang
standard
curv
replac
half
minimum
curv
valu
concentr
beyond
rang
standard
curv
replac
maximum
curv
valu
skin
biopsi
crosssect
portion
disrupt
homogen
lysisbind
buffer
thermo
fisher
scientif
use
homogen
lyse
matrix
z
mp
biomed
accord
manufactur
instruct
rna
purifi
mirvana
mirna
isol
kit
thermo
fisher
scientif
accord
manufactur
instruct
fifti
eluat
dnasetr
turbo
dnafre
kit
thermo
fisher
scientif
accord
manufactur
rigor
dnase
treatment
procedur
rna
result
dnasetr
sampl
purifi
use
rna
clean
kit
zymo
research
accord
manufactur
instruct
uniform
quantiti
total
rna
per
skin
biopsi
determin
nanodrop
thermo
fisher
scientif
read
use
creat
cdna
cdna
creation
perform
superscript
vilo
cdna
synthesi
kit
use
total
rna
transcript
quantif
perform
use
powerup
sybr
green
master
mix
thermo
fisher
scientif
accord
manufactur
instruct
cycl
paramet
quantstudio
flex
realtim
pcr
system
triplic
format
thermo
fisher
scientif
test
conduct
individu
primer
set
integr
dna
technolog
eotaxin
rela
tnf
rant
rigi
tabl
method
use
order
calcul
fold
chang
differ
sampl
time
point
rel
time
ct
valu
triplic
well
averag
find
meanct
valu
gene
interest
per
sampl
meanct
valu
averag
togeth
gener
mean
normal
factor
util
housekeep
gene
calcul
undetect
valu
artifici
set
maximum
detect
ct
valu
per
target
round
nearest
order
enabl
rel
quantif
histopatholog
analysi
conduct
skin
biopsi
specimen
tissu
section
immersionfix
neutral
buffer
formalin
embed
paraffin
section
stain
hematoxylin
eosin
dermatitispannicul
score
none
minim
mild
moder
mark
boardcertifi
anatom
pathologist
hematolog
analysi
perform
use
whole
blood
sampl
collect
purpletop
edta
tube
day
hematolog
analysi
conduct
use
sysmex
hematolog
analyz
sysmex
america
lincolnshir
il
hematolog
paramet
analyz
includ
white
blood
cell
wbc
count
red
blood
cell
rbc
count
hemoglobin
hgb
percentag
hematocrit
hct
mean
corpuscular
volum
mcv
mean
corpuscular
hemoglobin
mch
mean
cell
hemoglobin
concentr
mchc
platelet
plt
count
red
cell
distribut
width
rdw
mean
platelet
volum
mpv
reticulocyt
percentag
reticulocyt
count
refer
rang
util
inhous
interv
base
upon
routin
physic
rhesu
monkey
wrair
anim
coloni
involv
studi
serum
chemistri
analysi
obtain
whole
blood
collect
goldtop
serum
separ
tube
serum
analyz
aspart
aminotransferas
ast
alanin
transaminas
alt
use
vitro
chemistri
system
ortho
clinic
diagnost
raritan
nj
statist
analys
perform
accord
data
distribut
type
follow
rnaemia
viremia
data
compar
follow
way
auc
peak
magnitud
durat
onset
auc
peak
magnitud
analyz
use
logtransform
valu
onset
durat
analyz
use
untransform
valu
differ
test
use
anova
estim
obtain
auc
peak
magnitud
estim
mean
logvalu
geometr
mean
result
present
ratio
geometr
mean
calcul
pairwis
comparison
discuss
fold
chang
onset
durat
estim
obtain
differ
mean
present
statist
signific
clinic
valu
assess
chang
baselin
analyz
via
anova
baselin
valu
variabl
baselin
weight
group
factor
analys
transcript
data
base
fold
chang
baselin
deriv
method
fold
chang
valu
consid
biolog
meaning
transcript
data
antibodi
data
compar
group
sc
group
anova
model
fit
fold
chang
transcript
data
antibodi
data
includ
group
time
group
time
fix
effect
time
consid
repeat
measur
unstructur
covari
matrix
heterogen
varianc
group
assum
geometr
mean
geometr
mean
ratio
respect
ci
deriv
model
adjust
multipl
perform
data
analys
perform
use
sa
version
rstudio
r
version
test
perform
twotail
test
signific
assess
